On Dec. 4, 2025, Juan C. Jaen, President of Arcus Biosciences, sold 82,997 shares indirectly for ~$2.1 million, representing 5.91% of total holdings. The sale was executed through a trust, with no direct shares involved, reflecting accelerated disposition as remaining capacity declined. The shares were sold at a weighted average price of $24.71 per share. Arcus Biosciences focuses on developing oncology therapies and has a promising lead kidney cancer program despite a recent clinical setback. Investors may find opportunities in the stock’s volatility, but the company remains dependent on successful trial execution.

Read more at Nasdaq: Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return